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Background. Recent theories suggest that poor working memory (WM) may be the cognitive underpinning of negative
symptoms in people with schizophrenia. In this study, we ﬁrst explore the effect of cognitive remediation (CR) on two
clusters of negative symptoms (i.e. expressive and social amotivation), and then assess the relevance of WM gains as a
possible mediator of symptom improvement.
Method. Data were accessed for 309 people with schizophrenia from the NIMH Database of Cognitive Training and
Remediation Studies and a separate study. Approximately half the participants received CR and the rest were allocated
to a control condition. All participants were assessed before and after therapy and at follow-up. Expressive negative
symptoms and social amotivation symptoms scores were calculated from the Positive and Negative Syndrome Scale.
WM was assessed with digit span and letter-number span tests.
Results. Participants who received CR had a signiﬁcant improvement in WM scores (d = 0.27) compared with those in
the control condition. Improvements in social amotivation levels approached statistical signiﬁcance (d =−0.19), but
change in expressive negative symptoms did not differ between groups. WM change did not mediate the effect of CR
on social amotivation.
Conclusions. The results suggest that a course of CR may beneﬁt behavioural negative symptoms. Despite hypotheses
linking memory problems with negative symptoms, the current ﬁndings do not support the role of this cognitive domain
as a signiﬁcant mediator. The results indicate that WM improves independently from negative symptoms reduction.
Received 2 November 2016; Revised 1 March 2017; Accepted 1 March 2017
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Introduction
Despite the signiﬁcance of negative symptoms to the
prognosis of schizophrenia treatment options for this
symptom cluster are still relatively limited (Messinger
et al. 2011; Fusar-Poli et al. 2015). This may be because
we have not deﬁned a target that may impact on these
symptoms. One potential mediator has been identiﬁed
in recent empirical and theoretical work which links
negative symptoms and cognitive deﬁcits in people
with schizophrenia. In particular, Gold et al. (2008)
suggest that problems in working memory (WM)
may disrupt motivation and the pleasure experience.
These authors hypothesised that, in order to recruit
motivational resources, individuals use WM to represent
events and forecast pleasure. According to this model,
deﬁcits in WM could limit the ability to accurately
retrieve and use information to motivate and guide
future behaviour. This theory has some empirical sup-
port as WM performance predicts the accuracy of past
pleasure experience (Burbridge & Barch, 2007). More
recently, activity in WM brain networks has been asso-
ciated with improvement in negative symptoms fol-
lowing antipsychotic initiation suggesting that WM
may interact with treatment to inﬂuence outcomes
(Nejad et al. 2013). Although a number of hypotheses
have been proposed the latter study is the only one
to investigate the mediating effect of WM on negative
symptoms changes in the context of an intervention.
Although not an elective target for cognitive remedi-
ation (CR), the most recent meta-analysis reported that
CR has a small but signiﬁcant effect on symptoms of
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schizophrenia (Wykes et al. 2011). Among studies
reporting a positive effect, the majority suggest that
the negative symptom cluster is more likely to improve
after CR compared with the positive symptom cluster
(e.g. Gharaeipour & Scott, 2012; Farreny et al. 2013;
Sanchez et al. 2014; Cella et al. 2014b). The effect of
CR on negative symptoms is consistent with associa-
tions between negative symptoms and cognitive pro-
blems often found in patients with schizophrenia
(Milev et al. 2005; Ventura et al. 2009). Despite these
encouraging results it is still relatively unclear which
active ingredients of CR may contribute to negative
symptom improvements. The framework proposed
by Gold and co-workers (Gold et al. 2008; Gold et al.
2012) seems a potential candidate to explain how
improvements in cognitive domains targeted by CR
(e.g. WM) may inﬂuence negative symptoms. Indeed,
based on this theory Strauss (Strauss, 2013) suggested
that CR may be a useful intervention to tackle behav-
ioural negative symptoms.
The current study investigates for the ﬁrst time the
potential beneﬁt of CR for negative symptoms and
tests the mediating role of WM as a possible cognitive
mechanism. However, the domain of negative symp-
toms encompasses a wide range of problems, from
social behaviour to motivation as well as difﬁculties
in affect display and lack of spontaneity. In an attempt
to reduce negative symptom heterogeneity, factor ana-
lytic studies have explored solutions that produce
more coherent clusters. The overwhelming majority
of these studies support two distinct domains: one
characterised by expressive deﬁcits, including ﬂat
affect and alogia, and the other characterised by behav-
ioural problems such as avolition, asociality and anhe-
donia (Kirkpatrick and Fischer, 2006; Messinger et al.
2011). Distinguishing between these two sub-domains
may be important in the context of intervention
because the ‘active ingredients’ of therapies may have
a selective effect on only one cluster. So in this study
we consider these two distinct negative symptom
dimensions characterised by: (i) lack of expressivity
and (ii) poor social motivation. By exploring mediation
pathways this study will test the framework proposed
by Gold et al. (2008) in the context of an intervention.
Change in WM produced by therapy will allow an
evaluation of the links between negative symptoms
and WM. By analysing the individual level data from
different trials, this study will also allow an estimate
of how consistent the results will be across different
settings and allow a more accurate estimation of the
effect size (Riley et al. 2010).
This study will not only explore the effects of CR on
an understudied target but also investigate the
mechanisms responsible for this change by examining
potential mediational pathways. CR studies have
preferentially focused on evaluating effectiveness, but
paid only limited attention to study how effectiveness
is achieved (i.e. therapy mechanisms). Work in this dir-
ection, even if exploratory, can prove important in
improving current intervention approaches and maxi-
mise beneﬁts.
In this study, we expect CR to have a selective effect
on behavioural negative symptoms and anticipate, in
line with Gold et al. (2008) that improvement in WM
following CR will partly or fully mediate the change
in behavioural but not expressive negative symptoms.
Method
This study used data included in the NIMH Database
of Cognitive Training and Remediation Studies
(DoCTRS). This database assembled data at the indi-
vidual level from randomised, controlled trials of CR
in people with schizophrenia. For this paper, we ana-
lysed data from three studies entered in DoCTRS
(Wykes et al. 2007; Bell et al. 2008; Keefe et al. 2012)
and data from an unpublished, non-DoCTRS study
(Reeder et al. Submitted). This latter study is not yet
included in the database as it was recently completed
and currently under review for publication. These
studies were selected because they all assessed WM
and negative symptoms.
Design
In the four trials analysed, CR was compared with a
control condition, randomisation was conducted inde-
pendently and assessors were blind to group alloca-
tion. Treatment duration ranged from 12 to 16 weeks.
Post-treatment follow-up periods ranged from 24 to
32 weeks. Participants were assessed at intake into
the study (Baseline); at the end of treatment
(Post-treatment) and at Follow-up. No therapy was
provided between post-therapy and follow-up.
Participants
Participants had a primary diagnosis of schizophrenia
or schizoaffective disorder according to DSM-IV cri-
teria and were aged 18–65 years. Exclusion criteria
were neurological diseases, traumatic brain injury, a
history of learning disability, current substance abuse
and poor understanding of English. Participants were
recruited in the UK (Wykes et al. 2007; Reeder et al.
Submitted) and in the USA (Bell et al. 2007; Keefe
et al. 2012).
Therapy
The CR employed consisted primarily of task practice
engaging various cognitive domains, including WM,
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attention, processing speed, long-term memory and
executive function. Additional information on the dif-
ferent types of CR used and control conditions is sum-
marised in Table 1.
Measures
Demographic and cognitive data
Basic demographic information was collected on all
participants. Premorbid IQ was estimated using the
WRAT-R (Kareken et al. 1995) or the NAART (Uttl,
2002). Scores were compared using the guidelines pro-
posed by Johnstone et al. (1996).
Symptoms
Symptoms were assessed with the Positive and
Negative Syndrome Scale (PANSS, Kay et al. 1987).
This is a 30-item measure of symptom severity for peo-
ple with schizophrenia. The measure is administered
as a clinical interview by a trained researcher or clin-
ician. Each item is scored on a 7-point scale ranging
from not symptomatic (i.e. 1) to extremely severe
symptom (i.e. 7). For this study, we scored the
PANSS according to Liemburg et al. (2013) and used
the two dimensions of negative symptoms identiﬁed
in their study: Expressive Negative Symptoms (i.e.
ﬂat affect, poor rapport, lack of spontaneity, manner-
isms and posturing, motor retardation and avolition)
and social amotivation (emotional withdrawal, pas-
sive/apathetic social withdrawal and active social
avoidance).
Working memory
WM was assessed using two well-established tests: the
Digit Span test from the Wechsler Adult Intelligence
Scale (WAIS–III; Wechsler, 1987) and the Letter-Number
Span from the MATRICS Consensus Cognitive Battery
(Nuechterlein et al. 2008). Only Keefe et al. (2012) used
the Letter-Number Span. Scores on these tests are
reported in standardised Z-scores.
Analysis
The analysis was conducted in two stages. First, we
investigated whether individuals randomised to CR
showed greater improvement in WM and symptoms
compared with TAU at Post-treatment and Follow-up
assessments. We conducted a mixed effects analysis
based on the intention-to-treat principle. The baseline
score of the outcome variable was included as a covari-
ate [analysis of covariance (ANCOVA) approach]. The
model considered time (i.e. both Baseline and
Follow-up assessments), treatment group and the
interaction between time and group as ﬁxed T
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categorical variables. Study was also included as a cat-
egorical ﬁxed factor. An unstructured covariance
matrix allowing unequal variances and covariances
(i.e. correlations) between repeated measures and study
was used to account for repeated observations over
time (Brown & Prescott, 2006). Maximum-likelihood
estimation was used to estimate parameters for models
analysing all available data in the presence of missing
data, including no observations in Keefe at follow-up
(Brown & Prescott, 2006).
Interactions between study and time or treatment,
respectively, were assessed using the Bayesian infor-
mation criteria (BIC). Model selection was performed
by assessing change in BIC values with changes larger
than 10 providing evidence in support of excluding
interaction terms (Raftery, 1995). BIC changes were
only reported if the p value for the interaction statistics
was smaller than 0.1. Cohen’s d (i.e. predicted mean
difference divided by baseline standard deviation) is
presented as an estimate of effect size.
Sensitivity analyses were conducted to control for
individual studies unduly inﬂuencing the results. We
reran the models: (i) without Keefe et al. to control
for missing observations at follow-up, (ii) without
each of the other studies in turn to control for potential
difference in treatments and (iii) including only partici-
pants with completed cases to assess if people with
missing data inﬂuence the results of the analysis. As
WM and negative symptoms vary by age, we con-
ducted a further sensitivity analyses, including age as
a covariate in the model. We will report the results of
these analyses only when they alter the primary ana-
lysis results.
In the second stage, we performed a path analysis to
assess possible mediating effects (Baron & Kenny,
1986; MacKinnon & Luecken, 2008). Mediation is a
hypothesised causal chain in which one independent
variable (i.e. CR) affects a mediating variable (i.e.
WM), which, in turn, affects the outcome variable
(i.e. social amotivaton or expressive negative symptoms).
Multiple-group path analysis was employed to
examine and test whether differences in the path para-
meters across studies were statistically signiﬁcant.
Testing for cross-group invariance involved comparing
a baseline model where all parameters were con-
strained to be invariant between the groups with a
model where no constraints were speciﬁed. Path mod-
els were ﬁtted using full maximum-likelihood estima-
tion. The Sobel test was used to calculate standard
errors of the indirect effects. Comparison of nested
models employed a nested Chi-square (χ2) test. For
all variables we included a path to control for baseline
differences in the measures (ANCOVA approach;
MacKinnon, 2008). Mixed effects model analyses
used STATA 13.1 and path analyses using AMOS 22.
Results
Data from 309 participants who completed the baseline
assessment and were randomised were included in the
analyses (i.e. 157 CR and 152 control). Table 1 shows
the demographic and clinical characteristics of the
two groups at baseline. Positive and general symptoms
did not change over time in either groups (Table 2).
Does CR directly affect WM?
Participants who received CRT signiﬁcantly improved
their WM compared to those in the control groups at
Post-treatment [mean difference: 0.31 (95% CI 0.12–
0.50), z = 3.16, p = 0.002, d = 0.27], but the difference
was not signiﬁcant at Follow-up [mean difference:
0.10 (95% CI −0.10 to 0.30), z = 1.02, p = 0.31, d = 0.09].
There was no main effect of study on WM [χ2 (3) =
2.74, p = 0.43]. The interactions between time and
study (p = 0.83) and treatment group and study (p =
0.62) were not signiﬁcant and therefore not included
in the model. Adding age as a covariate did not inﬂu-
ence the outcome (p = 0.26).
Does CR directly affect social amotivation?
The mixed model analyses at post-treatment revealed a
trend towards a signiﬁcant interaction between treat-
ment group and time for social amotivation after
controlling for social amotivation baseline [mean dif-
ference 0.76 (−0.05 to 1.57) z = 1.85, p = 0.07, d = 0.11].
Participants who received CR showed a signiﬁcant
beneﬁt compared with those in the control groups at
post-treatment [mean difference: −1.29 (95% CI −1.79
to −0.78, z =−4.99, p < 0.0001, d =−0.19], but this dif-
ference was not maintained at follow-up [mean differ-
ence: −0.53 (95% CI −1.34 to 0.29), z =−1.27, p = 0.21,
−0.08]. There were no signiﬁcant differences between
study sites (p = 0.27). The interactions between time
and study (p = 0.63) and treatment group and study
(p = 0.53) were not signiﬁcant and not included in the
ﬁnal model. Adding age as a covariate did not inﬂu-
ence this result (p = 0.6).
Does CR directly affect expressive negative
symptoms?
There were no signiﬁcant differences in expressive
negative symptoms between CR and the control
group at Post-treatment [mean difference between CR
and TAU =−0.11 (95% CI −0.87 to 0.66), z =−0.28,
p = 0.78, d = 0.01] or Follow-up [−0.11 (95% CI −0.97
to 1.05), z = 0.08, p = 0.94, d = 0.01]. There were signiﬁ-
cant differences between studies [χ2(3) = 7.86, p =
0.049). The interaction between treatment group and
time was not signiﬁcant [0.15, (95% CI −0.91 to 1.21),
z = 0.28, p = 0.82, d = 0.01). The interactions between
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time and study (p = 0.50) and treatment group and
study (p = 0.06, BIC difference: 11.2) were not signiﬁ-
cant and not included in the model. Adding age as a
covariate did not inﬂuence this result (p = 0.55)
(Table 3).
Does WM improvement mediate improvements in
negative symptoms?
Because the previous analyses revealed no treatment
effect in expressive negative symptoms and social
amotivation at follow-up we restricted the mediation
analysis to the post-therapy time point. A multi-group
mediation analysis showed that the CR treatment effect
on social amotivation was not mediated by WM [con-
strained model: indirect effect across groups: b =−0.05
(95% CI −0.13 to 0.029), z = 1.22, p = 0.22, standardised
b: −0.009] (see Figure 1). The constrained model was
signiﬁcantly different from the unconstrained model
[χ2(54) = 151.3, p < 0.0001] and path models therefore
differed among source studies. Standardised indirect
effects of individual studies ranged from −0.189 to
+0.05 and were all non-signiﬁcant (Bell: b = 0.05, S.E. =
0.10 z = 0.44, p = 0.66, st.b = 0.009, N = 77; Wykes:b
−0.10, S.E. = 0.092, z =−1.09, p = 0.27, st.b. =−0.018, N
= 86; Reeder: b =−0.189, S.E. = 0.23, z =−0.83, p = 0.41,
st.b. =−0.035, N = 93; Keefe: b = 0.037, S.E. = 0.09, z =
0.63, p = 0.53, st.b = 0.00, N = 53).
The pooled indirect effect of WM between CR treat-
ment and expressive negative symptoms was close to 0
[constrained model indirect effect: −0.008 (95% CI
−0.132 to 0.116), z = 1.01, p = 0.31, st. beta: −0.001].
Indirect effects of individual studies ranged from
−0.155 to 0.027 (standardised betas from −0.017 to
0.003, all non-signiﬁcant).
Discussion
Our results further point to a possible beneﬁcial effect
of CR on negative symptoms. These analyses, how-
ever, show that improvements may only apply to a
sub-set of negative symptoms characterised by less
expressive and more behavioural features. This effect
is evident, at trend signiﬁcance level, immediately fol-
lowing therapy, but not retained at follow-up.
Increasingly, research reports suggest that negative
symptom heterogeneity may be a signiﬁcant factor to
consider when evaluating the effects of treatment
(Levine & Leucht, 2014). Recent research showed that
this is the case in CR for people with schizophrenia
(Cella et al. 2014b) and supports the use of more homo-
geneous and empirically deﬁned symptoms cluster
when evaluating treatment effects. The results of previ-
ous studies exploring the effects of CR on the symp-
toms of schizophrenia might have suffered from
conﬂating information from scales that use heteroge-
neous symptom clusters with mixed associations
with cognitive problems.
Contrary to our hypothesis, the current results sug-
gest that WM does not mediate the effect of CR on
social amotivation. This result is at odds with the
model proposed suggesting that WM deﬁcits nega-
tively inﬂuence reward-related processes and contrib-
ute to behavioural negative symptoms (Gold et al.
2008). We demonstrated that in the context of an inter-
vention targeting cognitive difﬁculties, improvement
Table 2. Demographics and clinical characteristics for the two
groups
CR (N = 157)
Mean (S.D.)
or %
Control
(N = 152)
Mean (S.D.)
Gender (male) 68.2% 66.9%
Age (years) 38.3(10.3) 37.1(9.7)
Education (years) 12.8(2.3) 12.4(2.4)
Illness onset over 10 years ago 56.1% 53.7%
Premorbid IQ 93.5(13.1) 91.7(13.6)
PANSS Positive 13.4(5.7) 14(5.9)
PANSS Negative 15.1(6.6) 15.9(6.9)
PANSS General 30.8(9.2) 31.2(9.5)
Medication
Atypical 68.7% 62.5%
Typical 14.7% 29.2%
Both 16.6% 8.6%
The PANSS factors scores presented are according to Kay
et al. (1987).
Table 3. Means and standard deviations for expressive negative
symptoms, (Exp Neg), social amotivation (Soc Amot) and working
memory (WM) for control group and the cognitive remediation (CR)
groups at the three assessments points
Control
CR N
Mean (S.D.) N Mean (S.D.) N
Exp Neg
Baseline 11.47 (5.25) 149 11.70 (5.10) 156
Post-treatment 10.88 (4.66) 137 10.95 (4.54) 146
Follow-up 10.51 (4.83) 93 10.87 (4.17) 93
Soc Amot
Baseline 6.86 (2.84) 149 7.2 (2.89) 156
Post-treatment 7.19 (3.1) 139 6.11 (2.56) 148
Follow-up 6.5 (3.4) 101 6.18 (2.93) 97
WM
Baseline −0.79 (1.21) 147 −0.73 (1.11) 154
Post-treatment −0.74 (1.24) 136 −0.39 (1.03) 142
Follow-up −0.67 (1.25) 99 −0.55 (1.01) 101
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in WM did not contribute to negative symptom change
and improvements in these domains occurred inde-
pendently. This does not rule out the contribution of
WM or cognition to negative symptoms. In this
study, we could only assess the role of verbal WM
on negative symptoms because of the assessment mea-
sures used. It is possible, as some studies suggested
that visual WM may be contributing more strongly
to negative symptoms severity (Pantelis et al. 2001).
Alternatively, other cognitive domains may be contrib-
uting to negative symptoms. Difﬁculties in planning
and organising information may contribute to disorga-
nised behaviour, decreased motivation and less pleas-
ure from experience. Indeed, some research suggests
that this may be the case but no speciﬁc theory of the
mechanism has yet been advanced (Fraguas et al.
2014). The set of studies considered in the DoCTRS,
database did not allow an investigation of the contri-
bution of executive function because executive func-
tion was measured using different tests assessing
different competencies that only marginally over-
lapped (e.g. planning, shifting, inhibition). A planned
expansion of the DoCTRS database would allow
exploration of this question in the future.
Studies exploring the effects of CR on basic cognitive
processes may help us reﬁne our understanding of
potential translational mechanism and their relevance
to speciﬁc symptoms such as the negative symptoms
(Cella et al. 2015). An example of a promising transla-
tional mechanism for negative symptoms is reward
sensitivity. Poor sensitivity to feedback has been
extensively documented in people with psychosis
and is associated with both cognitive difﬁculties and
negative symptom severity (e.g. Gold et al. 2008;
Strauss et al. 2014). A recent study showed that a
course of CR is associated with improved sensitivity
to feedback and that improvements in this domain
are linked to negative symptoms reduction (Cella
et al. 2014a). Future studies should speciﬁcally explore
the role of reward sensitivity in the context of interven-
tions tackling negative symptoms as this may be a
promising mediator.
Alongside improving cognition it is possible that CR
may exert a positive effect on negative symptoms via
‘non-speciﬁc’ therapy elements including therapeutic
alliance and behavioural activation (e.g. session attend-
ance) (e.g. Huddy et al. 2012). These aspects are only
beginning to be explored and may be particularly
important for negative symptoms as they provide
social contact opportunities and promote goal-directed
behaviour.
There are a limited number of interventions cur-
rently available for negative symptoms and these
were found to have only a small effect (Fusar-Poli
et al. 2015). A recent meta-analysis suggested that CR
interventions have a moderate effect size on negative
symptoms and that this effect is largely durable
(Cella et al. 2016). The results of this study also suggest
that CR programmes using rehabilitation activities
alongside cognitive task practice and frequent personal
contact with a facilitator or therapist tend to have a
higher impact on negative symptoms. It is likely that
Fig. 1. The results of the path analysis investigating the mediating role of WM.
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by providing these elements these programs facilitated
learning consolidation and the use of new skills in
everyday life. This study demonstrates a similar effect,
but in the context of interventions that did not always
provide additional rehabilitation activities and inten-
sive therapist contacts. It is possible that by enhancing
these two components and focusing task practice on
the cognitive domains more strongly associated with
negative symptoms a much larger symptom reduction
could be observed.
A number of small studies have already attempted
to adapt established psychological interventions for
psychosis to include a more pronounced focus on
negative symptoms; however, the results are not very
encouraging (Velthorst et al. 2015). The current study
used a different approach and took advantage of a
database of completed studies to investigate the pres-
ence of a ‘signal’. This approach has the beneﬁt of
reducing possible bias associated with a therapy deliv-
ery method by combining the results of different stud-
ies. This approach is efﬁcient as it can be used to test
hypotheses without the need to collect new data.
Recent evidence suggests that using aggregates of indi-
vidual data should be preferred, where possible, to
traditional meta-analytic studies (Riley et al. 2010).
Some of the advantages of this methodology include:
screening for missing data, including recruitment site
in the analysis, replicating results, using standardised
analysis across different studies, testing model
assumption (e.g. complex interactions between time,
treatments and sites) and consistently adjusting for
baseline variables. Studies comparing the results of
individual data meta-analysis to traditional
meta-analytic approaches have shown that differences
in the results between these two methods can be siz-
able and inﬂuence practice (e.g. Berlin et al. 2002;
McCormack et al. 2004). This method is preferred as
the best source of evidence and should be used more
often in mental health research to consolidate current
evidence and inform best practice.
This study has limitations. The PANSS, despite
assessing negative symptoms, was not designed to
capture speciﬁc components of this symptom clusters
and it may be that the factors used for this study
only account for some features of these domains.
Although our analysis did not highlight any study
behaving as an outlier, it is possible that there may
be a group of studies that behave differently and that
this trend is not evident due to the restricted numbers
of studies. There is a considerable variability in the
neuropsychological assessment measures used by dif-
ferent studies and this limits the possibility of aggre-
gating data.
The current analyses also suggest that treatment-
related gains in WM and social amotivation may not
be maintained at follow-up. This result is at odds
with the most recent meta-analysis, which suggests
that cognitive gains are durable (Wykes et al. 2011).
The studies included in our analysis, with the excep-
tion of Bell et al. (2008), did not provide CR in the con-
text of other comprehensive rehabilitation
interventions. There is increasing support for the
notion that CR achieves more durable gains when
delivered alongside rehabilitation (McGurk et al.
2007; Bowie et al. 2012). With the majority of the pro-
grammes considered here not offering additional sup-
port, it is possible that the lack of treatment gain
retention may be dependent on lack of opportunities
to apply CR gains in a wider rehabilitative context.
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